西黄丸抑制胃癌细胞增殖及其血管生成拟态形成的机制探讨
[Abstract]:BACKGROUND: China is a high incidence of gastric cancer. The morbidity and mortality of gastric cancer are in the forefront of the incidence and mortality of the tumor in China. The formation of angiogenesis is the newly discovered form of angiogenesis in recent years. It is closely related to the poor prognosis of gastric cancer. The hypoxic micro-environment is one of the main factors to promote the formation of tumor angiogenesis, and has a close relationship with the syndrome of blood stasis and poison. The anti-cancer Nifang pill has the effects of promoting blood circulation and removing toxic materials and inhibiting various tumors, and we have speculated that the possible mechanism of the western yellow pill with the effects of removing toxic substance and promoting blood circulation can be realized by regulating the hypoxic microenvironment and further inhibiting the formation of the tumor blood vessel. Objective: To study the mechanism of XHuangwan to regulate the hypoxic microenvironment and to inhibit the formation of tumor angiogenesis, and to explore the internal target of the anti-tumor of Xihuang Wan and enrich the connotation of the blood-activating and detoxicating method in the treatment of the tumor. Methods: (1) Experimental group: blank group, Xihuang pill group, HIF-1 inhibitor (2-ME) group and combination group; (2) human gastric cancer MGC-803 cell line and CCK-8 method were used in vitro to detect the inhibition of the proliferation of the tumor cells, and the AV-PI method was used to detect the effect of Xhuang pill on the apoptosis of the tumor cells. The effect of sihuang pill on the cell cycle of the tumor was detected by RNA enzyme method. In vivo, the tumor model of MGC-803 was established by Balb/ c nude mice, and the effect of Xihuang pill on the tumor volume and quality of the transplanted tumor in nude mice was observed and measured. (3) The hypoxic cell culture model was established by using the hypoxia workstation. The model of the in vitro tumor cell model was established by three-dimensional culture, and the number of tubes in each group was calculated by using a PAS-CD31 immunochemical-immunohistochemical double-staining method in vitro. (4) RT-qPCR, Western-blot and IHC were used to detect the expression of VE-Cadherin, EphA2, MMP-2 and the expression of mRNA, p-EphA2 protein, HIF-1, Twin1 and mRNA in the blood vessels by RT-qPCR, Western-blot and IHC. And (5) screening the anti-tumor and regulating the related genes of the hypoxia pathway by using the HTA2.0 chip, and carrying out RT-qPCR verification. Results: (1) Xihuang Wan can inhibit the proliferation of MGC-803 cells, and show the concentration and time-dependence, IC50:24 h is 50.424. mu. g/ ml,48 h is 35.129.mu. g/ ml, 72h is 28.191. mu. g/ ml, and the growth of transplanted tumor in nude mice is inhibited. At the same time, it can promote the apoptosis of MGC-803 cells and block the cell cycle in G0/ G1 phase. (2) In vitro and in vivo MGC-803 cell-like tube formation model, Xihuang pill can significantly inhibit the formation of the in vitro hypoxia condition and the in-vivo MGC-803 pseudo-state pipeline, which is similar to that of 2-ME, and the combination group has the strongest inhibition effect on the formation of the quasi-state pipeline. (3) The expression of VE-Cadherin, MMP-2 and the expression of p-EphA2 in the in-vivo and in-vitro VE-Cadherin and MMP-2 can be reduced and the expression of p-EphA2 can be reduced in vivo and in vitro. The binding group could decrease the expression of EphA2 mRNA, but could not significantly affect the expression of its protein. The expression of HIF-1 and Twin1 mRNA and protein in the in vitro expression of HIF-1 and Twin1 were decreased in Xhuang Pills,2-ME and combination group. (4) The gene chip of HTA2.0 was used to screen the possible pathway target of XHuangwan, and it was found that the expression of 628 genes could be reduced significantly and the expression of 88 genes was up-regulated. Significant down-regulation of 9 lncRNA expression, up-regulation of 11 lncRNA expression, and a significant effect on 54 signal pathways. in combination with that result of the above research, the hypoxia signal path and the cell cycle signal path are selected for verification, and the expression of the protein mTOR on the HIF-1 protein can be reduced, the expression of the post-translational modification protein PHD2 and the VHL protein gene is promoted, and the cell cycle related protein (SMC3, CDC25C, CDC6, MCM3) gene expression level. Conclusion: Xihuang Wan can inhibit the expression of hypoxia-related mTOR-HIF-1-Twistl signal, (2) promote the expression of hypoxia-related protein PHD2 and VHL, (3) inhibit the expression of the related protein VE-Cadherin, MMP-2 and EphA2 protein phosphorylation in the blood vessel, and (4) inhibit the expression of SMC3, CDC25C and CDC6. The cell cycle-related gene expression, such as MCM3, can inhibit the proliferation of MGC-803 cells and the formation of angiogenesis in human gastric cancer.
【学位授予单位】:北京中医药大学
【学位级别】:博士
【学位授予年份】:2017
【分类号】:R285
【相似文献】
相关期刊论文 前10条
1 张诗武,高欣;血管生成拟态和血管生成及其意义[J];国外医学(肿瘤学分册);2003年03期
2 孙保存,张诗武,倪春生,刘志勇,戚红,张丹芳;377例双向分化恶性肿瘤血管生成拟态临床意义分析[J];中国肿瘤临床;2005年02期
3 苏敏;尧良清;丰有吉;金惠铭;;肿瘤微循环的新形式——血管生成拟态[J];国际病理科学与临床杂志;2006年01期
4 杜珂;龚志敏;陈怀云;;血管生成拟态的研究进展[J];临床医药实践;2010年04期
5 张元松;赵晖;;胃癌肉瘤组织中的血管生成拟态观察[J];中外医疗;2010年30期
6 姬海宁;辛彦;肖玉平;;血管生成拟态研究进展[J];中华肿瘤防治杂志;2011年21期
7 李聪;陈银生;陈忠平;;血管生成拟态及其分子机制的研究进展[J];中国神经肿瘤杂志;2011年04期
8 张凡;孙保存;赵秀兰;常永霞;;小鼠黑色素瘤移植瘤中血管生成拟态的时空变化[J];河北北方学院学报;2005年05期
9 孙保存;张诗武;赵秀兰;郝希山;;双向分化恶性肿瘤血管生成拟态分子机制初步研究[J];医学研究通讯;2005年09期
10 黄海波;韩振国;辛华;;血管生成拟态研究进展[J];吉林大学学报(医学版);2008年01期
相关会议论文 前9条
1 孟立祥;荚卫东;许戈良;李建生;黄河;高群;马金良;;肝癌细胞血管生成拟态体外研究[A];第十二届全国肝癌学术会议论文汇编[C];2009年
2 陈忠平;;胶质瘤血管生成拟态的分子靶点探讨[A];中华医学会神经外科学分会第九次学术会议论文汇编[C];2010年
3 岳伟英;陈忠平;;星形胶质细胞肿瘤中有肿瘤血管生成拟态现象吗?[A];第三届中国肿瘤学术大会教育论文集[C];2004年
4 陈忠平;;胶质瘤中的血管生成拟态现象和意义[A];中国医师协会神经外科医师分会第六届全国代表大会论文汇编[C];2011年
5 张诗武;孙保存;张丹芳;郭华;赵秀兰;;黑色素瘤细胞线形程序性坏死与血管生成拟态之间关系的形态学观察研究[A];第四届中国肿瘤学术大会暨第五届海峡两岸肿瘤学术会议论文集[C];2006年
6 陈银生;陈忠平;;胶质瘤干细胞血管生成拟态的分子机制研究[A];中华医学会神经外科学分会第九次学术会议论文汇编[C];2010年
7 孙保存;张诗武;赵秀兰;倪春生;刘岩雪;邱志强;郝希山;;双向分化恶性肿瘤血管生成拟态分子机制初步研究[A];第三届中国肿瘤学术大会教育论文集[C];2004年
8 李熳;谷彦军;张丹芳;赵秀兰;孙保存;;胃腺癌血管生成拟态的临床病理意义及其相关机制研究[A];中华医学会病理学分会2010年学术年会日程及论文汇编[C];2010年
9 孙保存;;肿瘤血管生成拟态:进展与挑战[A];第四届中国肿瘤学术大会暨第五届海峡两岸肿瘤学术会议教育集[C];2006年
相关重要报纸文章 前3条
1 刘道安 李运红 赵迎;恶性肿瘤血供方式新发现——血管生成拟态[N];健康报;2006年
2 刘道安 李运红 赵迎;双向分化恶性肿瘤存在血管生成拟态[N];中国医药报;2006年
3 记者 冯国梧 通讯员 李运红赵迎;恶性肿瘤血道转移之谜揭开[N];科技日报;2006年
相关博士学位论文 前10条
1 徐书刚;microRNA-584-3p和microRNA-let-7f调控胶质瘤细胞低氧诱导血管生成拟态的机制研究[D];山东大学;2016年
2 王勇;microRNA-26b-5p在肝癌上皮间充质转化和血管生成拟态形成中的作用研究[D];天津医科大学;2016年
3 郭秋均;西黄丸抑制胃癌细胞增殖及其血管生成拟态形成的机制探讨[D];北京中医药大学;2017年
4 王世勇;恶性神经上皮肿瘤的血管生成拟态及其对患者预后的影响分析[D];南方医科大学;2013年
5 王巍;血管生成拟态在喉癌中的临床意义分子机制的初步探讨[D];天津医科大学;2010年
6 杜静;缺氧在卵巢癌血管生成拟态形成中的作用研究[D];天津医科大学;2012年
7 刘文斌;肝细胞癌血管生成拟态的临床意义及分子机制研究[D];天津医科大学;2011年
8 朱芳;PI3K作为抗肺癌血管新生和血管生成拟态共同靶点的研究[D];华中科技大学;2010年
9 凌耿强;转化生长因子-β基因沉默抑制U251MG细胞形成血管生成拟态的实验研究[D];南方医科大学;2012年
10 黄敏;mTOR经HIF-1α调控脑胶质瘤血管生成拟态的机制研究[D];南方医科大学;2014年
相关硕士学位论文 前10条
1 杨立芬;卵巢癌SKOV3中Holoclone细胞的特性及其形成血管生成拟态的能力[D];河北医科大学;2015年
2 陈琳;低剂量节拍化疗对卵巢癌细胞SKOV3血管生成拟态的影响及其机制的探讨[D];河北医科大学;2015年
3 刘晓;组蛋白去乙酰化酶-3与胶质瘤血管生成拟态的相关性[D];南方医科大学;2015年
4 汤晓颖;XAV939对人肝癌HepG2细胞血管生成拟态的影响[D];重庆医科大学;2015年
5 李水仙;小分子化合物DMBT对乳腺癌血管生成拟态的作用及机制研究[D];山东大学;2016年
6 唐姣;cRGD通过下调uPA蛋白及逆转EMT抑制卵巢癌血管生成拟态形成[D];南方医科大学;2016年
7 李静;环氧合酶2在胃癌血管生成拟态形成中的作用及其分子机制[D];天津医科大学;2016年
8 曹阳;Epha2的表达沉默对PC3细胞生物学行为及血管生成拟态的影响[D];南华大学;2016年
9 胡汉祥;阻断环氧化酶2对PC-3细胞血管生成拟态影响机制的研究[D];南华大学;2016年
10 刘荣娜;低剂量节拍化疗对荷人卵巢癌裸鼠移植瘤血管生成拟态的影响及可能机制[D];河北医科大学;2016年
,本文编号:2498420
本文链接:https://www.wllwen.com/shoufeilunwen/yxlbs/2498420.html